In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection

作者：Giacobbi Nicholas S; Sluis Cremer Nicolas^*

来源：Antimicrobial Agents and Chemotherapy, 2017, 61(7): e00277-17.

DOI：10.1128/AAC.00277-17

• HIV-1
• MIV-150
• NNRTI
• antiretroviral resistance
• dapivirine
• prevention

Rilpivirine (RPV), dapivirine (DPV), and MIV-150 are in development as microbicides. It is not known whether they will block infection of circulating non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant human immunodeficiency virus type 1 (HIV-1) variants. Here, we demonstrate that the activity of DPV and MIV-150 is compromised by many resistant viruses containing single or double substitutions. High DPV genital tract concentrations from DPV ring use may block replication of resistant viruses. However, MIV-150 genital tract concentrations may be insufficient to inhibit many resistant viruses, including those harboring K103N or Y181C.

• 出版日期2017-7